BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024 07:01 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
February 26, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects...
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
February 23, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO®...
BioCryst to Present at Upcoming Investor Conferences
February 21, 2024 16:01 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care...
BioCryst Launches ORLADEYO® (berotralstat) in Italy
February 19, 2024 07:54 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA),...
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
February 12, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results...
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 05, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
January 05, 2024 16:01 ET
|
BioCryst Pharmaceuticals, Inc.
—ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2024 16:01 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...